CMPS

COMPASS Pathways Plc - Form 6-K Summary (Period Ended June 30, 2021)

Business Context and Reporting Period

This Form 6-K filing covers the three and six months ended June 30, 2021, for COMPASS Pathways Plc, a clinical-stage mental health care company. The Company is developing COMP360, a proprietary psilocybin therapy for treatment-resistant depression (TRD). As of the reporting date, the Company has not generated any revenue and remains in the pre-commercialization phase, focusing on late-stage clinical trials in Europe and North America.

Key Financial Metrics

Note: The Company reported no debt obligations as of June 30, 2021. Previous convertible notes were converted to equity in 2020.

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by $5.4 million (22%) for the six months ended June 30, 2021, compared to the prior year period, driven primarily by higher R&D spending.
• R&D Expense Growth: R&D expenses rose by $6.3 million, attributed to a $4.9 million increase in clinical trial expenses and a $2.2 million increase in personnel costs to support expanded digital activities and clinical operations.
• Share-Based Compensation: Non-cash share-based compensation decreased significantly by $7.8 million year-over-year. This reduction is largely due to the absence of accelerated vesting expenses recognized in the prior year related to a specific executive grant.
• Foreign Exchange Impact: The Company recorded a foreign exchange loss of $1.2 million for the six months ended June 30, 2021, compared to a gain of $1.1 million in the prior year. This shift resulted from translating USD-denominated cash balances (from IPO and follow-on offerings) against the GBP functional currency.
• R&D Tax Credit Benefit: The benefit from UK R&D tax credits increased to $4.1 million from $2.1 million, reflecting increased qualifying R&D expenditures.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes the cash balance of $316.3 million as of June 30, 2021, is sufficient to fund operating expenses and capital expenditures through 2024.
• Clinical Milestones: The Company plans to report data from its Phase IIb trial of COMP360 in late 2021. Enrollment was delayed by the COVID-19 pandemic but has since been completed.
• Capital Requirements: The Company expects to incur significant losses for the foreseeable future as it advances clinical trials, expands headcount, and prepares for potential commercialization. Future funding will likely require equity offerings, debt financing, or strategic collaborations.
• Regulatory Status Change: As of June 30, 2021, the market value of non-affiliate common stock exceeded $700 million. Consequently, the Company will lose its "Emerging Growth Company" status effective January 1, 2022, becoming a large accelerated filer with increased compliance and reporting costs.
• Risks: Key risks include the uncertainty of clinical trial outcomes, potential delays due to the COVID-19 pandemic, the need for additional capital, and the complexity of regulatory approval for psilocybin-based therapies.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the $316.3 million cash balance and the assumptions underpinning the 2024 liquidity projection.
• Clinical Trial Progress: Confirm the status of the Phase IIb trial enrollment and the timeline for late 2021 data readout.
• Follow-On Offering Details: Review the terms and net proceeds of the May 2021 follow-on offering ($154.8 million) to understand dilution impacts.
• Share-Based Compensation: Monitor future share-based compensation expenses, noting the significant decrease in the current period was due to the absence of one-time accelerated vesting.
• Regulatory Compliance Costs: Assess the potential impact of losing Emerging Growth Company status on future G&A expenses starting in 2022.